

REMARKS

Applicants submit herewith an Information Disclosure Statement (IDS). Prior to issuing the next Office Action, Applicants respectfully request that the Examiner make of record the references cited therein and return to the undersigned attorney an initialed copy of the IDS.

In response to the Restriction Requirement dated September 17, 2007, Applicants hereby elect Group III (claim 11) directed to a method of inhibiting VEGF production in a cell. As claim 11 refers to claims 1-7 which are not elected, claim 11 has been amended to incorporate language from claim 1. In view of the election of claim 11, Applicants have cancelled claims 1-10 and 12-14 without prejudice to pursue in a future related application. New claims 15-21 have been added to depend (directly or indirectly) from amended claim 11. The new claims find support in claim 11 as originally filed, as well as: claim 2 for claim 15; claim 3 for claim 16; claim 4 for claims 17 and 18; claim 5 for claim 19; claim 6 for claim 20; and claim 7 for claim 21. No new matter has been added by the amendment to claim 11 or the addition of new claims 15-21. Claims 11 and 15-21 are now pending.

In response to the request for a species election, Applicants hereby elect as the single disclosed species in order to initiate searching for examination:


3-[4-phenylthiazol-2-yl]-7-(N,N-diethylamino)-chromen-2-one.

The compound is disclosed in the application as filed, for example, as compound 46 on page 29; Example 8 on pages 7-8; and compound 36 on page 101.

Favorable consideration of the elected claims is now requested.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Richard G. Sharkey, Ph.D.

Registration No. 32,629

Customer No. 00500

Enclosures:

IDS Transmittal

IDS

Cited References (48)

Face pages of six U.S. Patents

MillicentS/1072438